Jenny Lam

发表

Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo

D. Gracias, Arijit Ghosh, Wangqu Liu, 2020, Science Advances.

A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder

A. Janowsky, Z. Xi, A. Newman, 2022, Neuropsychopharmacology.

A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder

A. Janowsky, Z. Xi, A. Newman, 2022, Neuropsychopharmacology.

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

Liang Zhao, T. Seiwert, A. Pal, 2022, Science advances.

The Effects of the Dopamine Transporter Ligands JJC8-088 and JJC8-091 on Cocaine versus Food Choice in Rhesus Monkeys

M. Nader, L. Porrino, S. Childers, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Synthesis of C-acyl furanosides via the cross-coupling of glycosyl esters with carboxylic acids

T. Diao, Jenny Lam, Yongliang Wei, 2021, Chemical science.

Structure-Activity Relationships for a series of bis(4-fluorophenyl)methyl)sulfinyl)alkyl alicyclic amines at the dopamine transporter: functionalizing the terminal nitrogen affects affinity, selectivity and metabolic stability.

A. Newman, Alessandro Bonifazi, C. Loland, 2019, Journal of Medicinal Chemistry.

Enhanced oral bioavailability of 2-(phosphonomethyl)-pentanedioic acid (2-PMPA) from its (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL) based prodrugs.

B. Slusher, P. Majer, R. Rais, 2019, Molecular pharmaceutics.

The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

C. Brayton, J. Blakeley, K. Lemberg, 2019, Molecular Cancer Therapeutics.

Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.

K. Lemberg, K. Novotná, B. Slusher, 2019, Journal of medicinal chemistry.

Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer disease.

B. Slusher, K. Hollinger, R. Rais, 2020, Journal of medicinal chemistry.

Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.

A. Newman, Alessandro Bonifazi, G. Tanda, 2020, European journal of medicinal chemistry.

Investigation of novel primary and secondary pharmacophores, and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists and partial agonists.

Z. Xi, A. Newman, Alessandro Bonifazi, 2019, Journal of medicinal chemistry.

The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists.

A. Newman, Alessandro Bonifazi, Gregory H. Imler, 2019, Journal of medicinal chemistry.

Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile.

A. Newman, C. Loland, R. Rais, 2023, Journal of medicinal chemistry.